Phillip Schwartz - 01 Jan 2022 Form 3 Insider Report for Entera Bio Ltd. (ENTX)

Role
President of R&D, Director
Signature
/s/ Dana Yaacov-Garbeli, Attorney-in-fact
Issuer symbol
ENTX
Transactions as of
01 Jan 2022
Transactions value $
$0
Form type
3
Filing time
11 Jan 2022, 15:04:44 UTC
Next filing
24 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ENTX Ordinary Shares, par value NIS 0.0000769 per share 597,410 01 Jan 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ENTX Stock Option (right to buy) 01 Jan 2022 Ordinary Shares, par value NIS 0.0000769 per share 357,500 $6.31 Direct F1
holding ENTX Stock Option (right to buy) 01 Jan 2022 Ordinary Shares, par value NIS 0.0000769 per share 100,000 $3.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vested ratably on a quarterly basis over a four-year period commencing on February 23, 2018.
F2 The options vest over a four-year period that commenced on April 21, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

Remarks:

See Exhibit 24.1 - Power of Attorney